Placebo matched to ocrelizumab clinical trials

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

This study is comparing two medicines, fenebrutinib and ocrelizumab, to see which is safer and better at slowing down primary progressive multiple sclerosis (PPMS). It's for adults with PPMS and aims to understand how these treatments affect the disease progression.